ASCO Annual Meeting, Chicago, Illinois

Monday, June 1, 2015 poster session. Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma Multiforme (GBM)

106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania

Monday, April 20, 2015 poster session: VAL-083 Phase 1/2 data poster # CT217: Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma

106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania

Monday, April 20, 2015 poster session: VAL-083 GBM preclinical poster #2562: Dianhydrogalactitol inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo

106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania

Sunday, April 19, 2015 poster session: VAL-083 NSCLC preclinical poster # 751: In vitro activity of dianhydrogalactitol alone or with platinum drugs in the treatment of non-small cell lung cancer

VAL-083: GBM Historical Review & Strategy for Product Development

DelMar Preclinical Research Presented at Society for NeuroOncology Annual Meeting

DelMar in vitro data from SNO: Differentiation from Temozolomide

DelMar Clinical Data Presentation from SNO: Update on Phase I/II GBM Clinical Trial

VAL-083: NSCLC Historical Review & Strategy for Product Differentiation

DelMar's Presentation Poster at American Association of Cancer Research (AACR) New Horizons in Cancer Research Conference